A first clinical trial of NDI-219216.
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs NDI 219216 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- 16 Jan 2025 New trial record
- 09 Jan 2025 According to Nimbus Therapeutics Media Release, Company plans to initiate the first clinical trial of NDI-219216 in the first half of 2025 under the leadership of Anita Scheuber, M.D., Ph.D., Senior Vice President, Therapeutic Area Head, Oncology.